Guidant Makes Good On MADIT II: Medicare, Referring Cardiologists Courted
This article was originally published in The Gray Sheet
Executive Summary
Guidant is confident about obtaining local Medicare coverage for the ICD indications in its MADIT II trial before initiating discussions with CMS late in 2002 to secure a national coverage decision
You may also be interested in...
Guidant MADIT II Trial Could Support Doubling Of ICD-Eligible Population
Favorable results of the Guidant-sponsored MADIT II trial could increase the U.S. patient population that could benefit from implantable cardioverter defibrillator therapy from 300,000 to about 600,000, Guidant says
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.